Literature DB >> 26122932

Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity.

Daniel O Villarreal1, Megan C Wise1, Rebekah J Siefert1,2, Jian Yan3, Laurence M Wood4, David B Weiner1.   

Abstract

ISG15 is an ubiquitin-like protein induced by type I interferon associated with antiviral activity. ISG15 is also secreted and known to function as an immunomodulatory molecule. However, ISG15's role in influencing the adaptive CD8 T-cell responses has not been studied. Here, we demonstrate the efficacy of ISG15 as a vaccine adjuvant, inducing human papilloma virus (HPV) E7-specific IFNγ responses as well as the percentage of polyfunctional, cytolytic, and effector CD8 T-cell responses. Vaccination with ISG15 conferred remarkable control and/or regression of established HPV-associated tumor-bearing mice. T-cell depletion coupled with adoptive transfer experiments revealed that ISG15 protective efficacy was CD8 T-cell mediated. Importantly, we demonstrate that ISG15 vaccine-induced responses could be generated independent of ISGylation, suggesting that responses were mostly influenced by free ISG15. Our results provide more insight into the immunomodulatory properties of ISG15 and its potential to serve as an effective immune adjuvant in a therapeutic tumor or infectious disease setting.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26122932      PMCID: PMC4817913          DOI: 10.1038/mt.2015.120

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  42 in total

1.  IFN-induced 15-kDa protein is released from human lymphocytes and monocytes.

Authors:  E Knight; B Cordova
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

2.  Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.

Authors:  Sima Rahimian; Marieke F Fransen; Jan Willem Kleinovink; Jonatan Riis Christensen; Maryam Amidi; Wim E Hennink; Ferry Ossendorp
Journal:  J Control Release       Date:  2015-02-07       Impact factor: 9.776

Review 3.  Similarities and differences in CD4+ and CD8+ effector and memory T cell generation.

Authors:  Robert A Seder; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-09       Impact factor: 25.606

4.  Co-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccination.

Authors:  Benjamin Anderschou Holbech Jensen; Maria Abildgaard Steffensen; Karen Nørgaard Nielsen; Jan Pravsgaard Christensen; Allan Randrup Thomsen; Peter Johannes Holst
Journal:  Mol Ther       Date:  2014-07-15       Impact factor: 11.454

5.  Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.

Authors:  Daniel O Villarreal; Jewell Walters; Dominick J Laddy; Jian Yan; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.

Authors:  G R Gunn; A Zubair; C Peters; Z K Pan; T C Wu; Y Paterson
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

7.  Distinct functional surface regions on ubiquitin.

Authors:  K E Sloper-Mould; J C Jemc; C M Pickart; L Hicke
Journal:  J Biol Chem       Date:  2001-06-08       Impact factor: 5.157

Review 8.  Trafficking of T cells into tumors.

Authors:  Clare Y Slaney; Michael H Kershaw; Phillip K Darcy
Journal:  Cancer Res       Date:  2014-12-04       Impact factor: 12.701

Review 9.  Central memory and effector memory T cell subsets: function, generation, and maintenance.

Authors:  Federica Sallusto; Jens Geginat; Antonio Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

10.  Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation.

Authors:  Xianqin Zhang; Dusan Bogunovic; Béatrice Payelle-Brogard; Véronique Francois-Newton; Scott D Speer; Chao Yuan; Stefano Volpi; Zhi Li; Ozden Sanal; Davood Mansouri; Ilhan Tezcan; Gillian I Rice; Chunyuan Chen; Nahal Mansouri; Seyed Alireza Mahdaviani; Yuval Itan; Bertrand Boisson; Satoshi Okada; Lu Zeng; Xing Wang; Hui Jiang; Wenqiang Liu; Tiantian Han; Delin Liu; Tao Ma; Bo Wang; Mugen Liu; Jing-Yu Liu; Qing K Wang; Dilek Yalnizoglu; Lilliana Radoshevich; Gilles Uzé; Philippe Gros; Flore Rozenberg; Shen-Ying Zhang; Emmanuelle Jouanguy; Jacinta Bustamante; Adolfo García-Sastre; Laurent Abel; Pierre Lebon; Luigi D Notarangelo; Yanick J Crow; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Sandra Pellegrini
Journal:  Nature       Date:  2014-10-12       Impact factor: 49.962

View more
  15 in total

1.  IFN-Stimulated Gene 15 Is an Alarmin that Boosts the CTL Response via an Innate, NK Cell-Dependent Route.

Authors:  Victoria Iglesias-Guimarais; Tomasz Ahrends; Evert de Vries; Klaus-Peter Knobeloch; Andriy Volkov; Jannie Borst
Journal:  J Immunol       Date:  2020-03-13       Impact factor: 5.422

Review 2.  Current state in the development of candidate therapeutic HPV vaccines.

Authors:  Andrew Yang; Jessica Jeang; Kevin Cheng; Ting Cheng; Benjamin Yang; T-C Wu; Chien-Fu Hung
Journal:  Expert Rev Vaccines       Date:  2016-03-07       Impact factor: 5.217

Review 3.  Immunotherapy for HPV Malignancies.

Authors:  Maxwell Y Lee; Clint T Allen
Journal:  Semin Radiat Oncol       Date:  2021-10       Impact factor: 5.421

4.  ISGylation is induced in neurons by demyelination driving ISG15-dependent microglial activation.

Authors:  Benjamin D S Clarkson; Ethan Grund; Kenneth David; Renee K Johnson; Charles L Howe
Journal:  J Neuroinflammation       Date:  2022-10-20       Impact factor: 9.587

5.  Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Michela Falqui; María Q Marín; Martina Bécares; Carlos Óscar S Sorzano; Juan García-Arriaza; Mariano Esteban; Susana Guerra
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

6.  ISG15 predicts poor prognosis and promotes cancer stem cell phenotype in nasopharyngeal carcinoma.

Authors:  Ren-Hui Chen; Yong Du; Ping Han; Hong-Bo Wang; Fa-Ya Liang; Guo-Kai Feng; Ai-Jun Zhou; Mu-Yan Cai; Qian Zhong; Mu-Sheng Zeng; Xiao-Ming Huang
Journal:  Oncotarget       Date:  2016-03-29

7.  Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.

Authors:  Daniel O Villarreal; Diana Chin; Melissa A Smith; Leopoldo L Luistro; Linda A Snyder
Journal:  Oncotarget       Date:  2017-06-13

8.  ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression.

Authors:  Tsz-Lun Yeung; Ching Chou Tsai; Cecilia S Leung; Chi-Lam Au Yeung; Melissa S Thompson; Karen H Lu; Ralph S Freedman; Michael J Birrer; Kwong-Kwok Wong; Samuel C Mok
Journal:  Cancers (Basel)       Date:  2018-11-22       Impact factor: 6.639

Review 9.  Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.

Authors:  Maryam Dadar; Sandip Chakraborty; Kuldeep Dhama; Minakshi Prasad; Rekha Khandia; Sameer Hassan; Ashok Munjal; Ruchi Tiwari; Kumaragurubaran Karthik; Deepak Kumar; Hafiz M N Iqbal; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-11-12       Impact factor: 7.561

10.  Conformational changes in myeloperoxidase induced by ubiquitin and NETs containing free ISG15 from systemic lupus erythematosus patients promote a pro-inflammatory cytokine response in CD4+ T cells.

Authors:  Daniel Alberto Carrillo-Vázquez; Eduardo Jardón-Valadez; Jiram Torres-Ruiz; Guillermo Juárez-Vega; José Luis Maravillas-Montero; David Eduardo Meza-Sánchez; María Lilia Domínguez-López; Jorge Carlos Alcocer Varela; Diana Gómez-Martín
Journal:  J Transl Med       Date:  2020-11-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.